

**IN THE CLAIMS**

1. (previously presented) A composition for treating a TH2 response and for inducing a cell mediated immune response comprising a TH1 response in an individual having a TH2/TH1 imbalance associated with a pro-tumor immune response, the composition comprising: an immunotherapeutic composition for effecting B cell depletion; and tumor-associated antigen capable of inducing a cell mediated immune response comprising a TH1 response.
2. (previously presented) The composition according to claim 1, further comprising a component selected from the group consisting of an immunomodulator for inducing a cell mediated immune response comprising a TH1 response, a pharmaceutically acceptable carrier, and a combination thereof.
3. (previously presented) The composition according to claim 1, wherein the immunotherapeutic composition is contained in a solid phase implant for delivery of the immunotherapeutic composition.
4. (previously presented) The composition according to claim 1, wherein the immunotherapeutic composition further comprises an anti-B cell agent.
5. (previously presented) The composition according to claim 1, wherein the immunotherapeutic composition comprises an affinity ligand having binding specificity for a determinant selected from the group consisting of CD19, CD20, CD21, CD22 (also known as LL2), CDIM, and Lym-1.
6. (canceled)
7. (previously presented) The composition according to claim 1, wherein the TH2/TH1 imbalance is mediated by a disease process comprising a pro-tumor immune response.

8. (previously presented) The composition according to claim 1, wherein the TH2/TH1 imbalance is mediated by a disease process comprising a pro-tumor immune response and solid nonlymphoid tumor.

9. (previously presented) A composition useful for the treatment of solid nonlymphoid tumor in an individual, the composition comprising: an immunotherapeutic composition for effecting B cell depletion; and tumor-associated antigen capable of inducing a cell mediated immune response comprising a TH1 response;

wherein the composition is in an amount effective to overcome a TH2/TH1 imbalance, the TH2/TH1 imbalance associated with a pro-tumor immune response, or a combination of the solid nonlymphoid tumor and a pro-tumor immune response.

10. (previously presented) The composition according to claim 9, further comprising a component selected from the group consisting of an immunomodulator for inducing a cell mediated immune response comprising a TH1 response, a pharmaceutically acceptable carrier, and a combination thereof.

11. (previously presented) The composition according to claim 9, wherein the immunotherapeutic composition further comprises an anti-B cell agent.

12. (previously presented) The composition according to claim 9, wherein the immunotherapeutic composition comprises an affinity ligand having binding specificity for a determinant selected from the group consisting of CD19, CD20, CD21, CD22 (also known as LL2), CDIM, and Lym-1.

13-68. (canceled)

69. (previously presented) A composition comprising:  
(a) an immunotherapeutic composition comprising a monoclonal antibody having binding specificity for CD22 for effecting B cell depletion; and

(b) tumor-associated antigen capable of inducing a cell mediated immune response comprising a TH1 response;

wherein the composition is in an amount effective for suppressing a TH2 response, and for inducing a cell mediated immune response comprising a TH1 response, in an individual having a TH2/TH1 imbalance associated with a pro-tumor immune response.

70. (previously presented) The composition according to claim 69, further comprising a component selected from the group consisting of an immunomodulator for inducing a cell mediated immune response comprising a TH1 response, a pharmaceutically acceptable carrier, and a combination thereof.

71. (previously presented) The composition according to claim 69, further comprising an immunomodulator for inducing a cell mediated immune response comprising a TH1 response.

72. (previously presented) The composition according to claim 69, wherein the immunotherapeutic composition further comprises a pharmaceutically acceptable carrier, and the tumor-associated antigen further comprises a pharmaceutically acceptable carrier.

73. (previously presented) The composition according to claim 70, wherein the component comprises an immunomodulator and a pharmaceutically acceptable carrier.

74-76. (canceled)

77. (previously presented) The composition according to claim 74, wherein the immunotherapeutic composition is contained in a solid phase implant for delivery of the immunotherapeutic composition.

78. (previously presented) The composition according to claim 69, wherein the immunotherapeutic composition further comprises an anti-B cell agent.

79. (canceled)

80. (previously presented) The composition according to claim 69, wherein the TH2/TH1 imbalance is mediated by a disease process comprising a pro-tumor immune response.

81. (previously presented) The composition according to claim 69, wherein the TH2/TH1 imbalance is mediated by a disease process comprising a pro-tumor immune response and solid nonlymphoid tumor.

82. (previously presented) A composition comprising:

(a) an immunotherapeutic composition comprising a monoclonal antibody having binding specificity for CD22 for effecting B cell depletion; and

(b) tumor-associated antigen capable of inducing a cell mediated immune response comprising a TH1 response;

wherein the composition is in an effective amount for the treatment, or inhibition of development, of solid nonlymphoid tumor in an individual having a pro-tumor immune response.

83. (previously presented) The composition according to claim 82, further comprising a component selected from the group consisting of an immunomodulator for inducing a cell mediated immune response comprising a TH1 response, a pharmaceutically acceptable carrier, and a combination thereof.

84. (previously presented) The composition according to claim 82, further comprising an immunomodulator for inducing a cell mediated immune response comprising a TH1 response.

85. (previously presented) The composition according to claim 82, wherein the immunotherapeutic composition further comprises a pharmaceutically acceptable carrier, and the tumor-associated antigen further comprises a pharmaceutically acceptable carrier.

86. (previously presented) The composition according to claim 83, wherein the component comprises an immunomodulator and a pharmaceutically acceptable carrier.

87-89. (canceled)

90. (previously presented) The composition according to claim 82, wherein the immunotherapeutic composition further comprises an anti-B cell agent.

91. (canceled)

92. (previously presented) A composition comprising:

(a) an immunotherapeutic composition comprising a monoclonal antibody having binding specificity for CD22, for effecting B cell depletion in suppressing a TH2 response associated with a pro-tumor immune response or a combination of a pro-tumor immune response and solid nonlymphoid tumor; and

b) tumor-associated antigen capable of inducing a cell mediated immune response comprising a TH1 response.

93. (previously presented) The composition according to claim 92, further comprising a component selected from the group consisting of an immunomodulator for inducing a cell mediated immune response comprising a TH1 response, a pharmaceutically acceptable carrier, and a combination thereof.

94. (previously presented) The composition according to claim 93, further comprising an immunomodulator for inducing a cell mediated immune response comprising a TH1 response.

95. (previously presented) The composition according to claim 92, wherein the immunotherapeutic composition further comprises a pharmaceutically acceptable carrier, and the tumor-associated antigen further comprises a pharmaceutically acceptable carrier.

96. (previously presented) The composition according to claim 93, wherein the component comprises an immunomodulator and a pharmaceutically acceptable carrier.

97-99. (canceled)

100. (previously presented) The composition according to claim 92, wherein the immunotherapeutic composition further comprises an anti-B cell agent.

101. (canceled)

102. (previously presented) The composition according to claim 92, wherein the TH2/TH1 imbalance is mediated by a disease process comprising a pro-tumor immune response.

103. (previously presented) The composition according to claim 92, wherein the TH2/TH1 imbalance is mediated by a disease process comprising a pro-tumor immune response and solid nonlymphoid tumor.

104. (previously presented) A composition comprising:

(a) an immunotherapeutic composition comprising a monoclonal antibody having binding specificity for CD22 for effecting B cell depletion in suppressing a TH2 response; and

(b) tumor-associated antigen capable of inducing a cell mediated immune response comprising a TH1 response;

wherein the composition is in an amount effective to overcome a TH2/TH1 imbalance associated with a pro-tumor immune response, or a combination of solid nonlymphoid tumor and a pro-tumor immune response.

105. (previously presented) The composition according to claim 104, further comprising a component selected from the group consisting of an immunomodulator for inducing a cell mediated immune response comprising a TH1 response, a pharmaceutically acceptable carrier, and a combination thereof.

106. (previously presented) The composition according to claim 104, further comprising an immunomodulator for inducing a cell mediated immune response comprising a TH1 response.

107. (previously presented) The composition according to claim 104, wherein the immunotherapeutic composition further comprises a pharmaceutically acceptable carrier, and the tumor-associated antigen further comprises a pharmaceutically acceptable carrier.

108. (previously presented) The composition according to claim 105, wherein the component comprises an immunomodulator and a pharmaceutically acceptable carrier.

109-111. (canceled)

112. (previously presented) The composition according to claim 104, wherein the immunotherapeutic composition further comprises an anti-B cell agent.

113. (canceled)

114. (previously presented) The composition according to claim 104, wherein the TH2/TH1 imbalance is mediated by a disease process comprising a pro-tumor immune response.

115. (previously presented) The composition according to claim 104, wherein the TH2/TH1 imbalance is mediated by a disease process comprising a pro-tumor immune response and solid nonlymphoid tumor.